Rat ovarian angiotensin II receptors. Characterization and coupling to estrogen secretion.
Angiotensin II receptor agonist (125I-angiotensin II) and antagonist (125I-[Sar1,Ile8]angiotensin II) bind in a specific and saturable manner to rat ovarian membranes. Agonist and antagonist binding affinity (KD approximately 0.5 nM) and the number of sites estimated (Bmax approximately 60 fmol/mg of protein) were similar. Dissociation of receptor-bound agonist was more rapid than the dissociation of receptor-bound antagonist, and agonist, but not antagonist, dissociation from the receptor was accelerated by GTP gamma S. A 0-150 mM increase in Na+ produced a 27% increase in the KD of agonist binding. Antagonist binding was not modified by Na+. These studies suggest that both agonist and antagonist identify putative angiotensin II receptors in the ovary but that the properties of agonist and antagonist binding are distinct. Angiotensin II antagonist binding sites are present on the granulosa cell layer of rat ovarian follicles (Speth, R. C., Bumpus, F. M., and Husain, A. (1986) Eur. J. Pharmacol. 130, 351-352). To determine the role of angiotensin II in ovarian function, we examined angiotensin II receptors and function during the onset of puberty. High affinity and low capacity angiotensin II receptors were present in ovaries from immature rats. After pregnant mare's serum gonadotropin induced ovulation in immature rats, antagonist binding to total ovarian membranes increased over 3-fold. In vitro incubation of peripubertal ovaries with 1 microM angiotensin II produced a stimulation of estrogen, but not progesterone, secretion. This steroidogenic effect of angiotensin II was most pronounced in the luteal phase of the estrus cycle. These studies point toward the involvement of angiotensin II in the regulation of ovarian function, possibly through modulation of follicular estrogen levels.
Pucell
A G
AG
Bumpus
F M
FM
Husain
A
A
D015059:1-Sarcosine-8-Isoleucine Angiotensin II / Q000378:metabolism; D000804:Angiotensin II / Q000378:metabolism; D000818:Animals; D002462:Cell Membrane / Q000378:metabolism; D004967:Estrogens / Q000378:metabolism*; D004971:Estrus / Q000378:metabolism; D005260:Female; D006064:Gonadotropins, Equine / Q000494:pharmacology; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D006160:Guanosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D010053:Ovary / Q000502:physiology*; D010060:Ovulation; D011374:Progesterone / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D011945:Receptors, Angiotensin / Q000502:physiology*; D012741:Sexual Maturation; D012964:Sodium / Q000494:pharmacology; D013873:Thionucleotides / Q000494:pharmacology
D004967:Estrogens; D006064:Gonadotropins, Equine; D011945:Receptors, Angiotensin; D013873:Thionucleotides; D000804:Angiotensin II; D016244:Guanosine 5'-O-(3-Thiotriphosphate); D011374:Progesterone; D006160:Guanosine Triphosphate; D015059:1-Sarcosine-8-Isoleucine Angiotensin II; D012964:Sodium